Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolution of growth rate in children with growth retardation related to long-term glucocorticoid therapy
2004-002992-17Phase 3
- Sponsor
- Pfizer
- Start
- May 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin, sponsored by Pfizer. Primary endpoint: Primary: Change in height SDS after 3 years of GH treatment.
02
Drugs
somatropin
Beyond the preview
Go deeper on 2004-002992-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002992-17.